Approved, Compounded or “Research Use Only”: What a Peptide’s Label Means in 2026

The story below is a composite of real experiences; details changed.

“FDA just approved BPC-157.”

The rookie holds up his phone across the firehouse breakfast table. Paul Donnelly, 52, a captain with 27 years on the job, has read enough headlines to know that’s probably not what happened.

It isn’t. In July, an FDA advisory panel voted, and that’s not the same thing. If peptide news feels like it changes every few months, that’s because it has.

Paul asks the question nobody at the table can answer: “Approved by who, for what?”

Here’s what each label means, where BPC-157 and TB-500 stand as of September 24, 2026, and how to check the next headline yourself.

Lane 1: FDA-approved

Approval means FDA reviewed the data and found that a drug’s benefits outweigh its known and potential risks for the people it’s meant for. (FDA) The review also checks that manufacturing protects the drug’s “identity, strength, quality, and purity.” (FDA)

Peptides can be approved drugs. Glucagon, liraglutide and teriparatide are examples. (FDA)

BPC-157 isn’t one. FDA’s 2026 review found “no approved product containing BPC-157-related BDSs in any country at this time.” (FDA)

Lane 2: Compounded

Compounding means a licensed pharmacist or physician combines, mixes or alters ingredients to make a medication for one patient. Compounded drugs aren’t FDA-approved. FDA doesn’t review their safety, effectiveness or quality before they’re sold. (FDA)

A pharmacy can compound from a bulk ingredient only if it:

1. Meets an official USP or NF quality standard (a monograph), or
2. Is part of an FDA-approved drug, or
3. Is on FDA’s list of allowed bulk ingredients, called the 503A bulks list.

(FDA)

BPC-157 has no monograph, isn’t part of an approved drug and isn’t on the list. As of September 21, 2026, that list held six substances and no peptides. (eCFR)

Vote counts come from press and law-firm reports, including PharmExec and STAT. FDA hadn’t posted official minutes when we checked. FDA staff positions are from the FDA briefing.

For what the studies behind the hype actually found, read what the BPC-157 research actually shows.

What the July vote did, and didn’t do

• 2023: BPC-157 and related peptides were placed in FDA’s Category 2, for ingredients with significant safety risks. (Frier Levitt)
• April 2026: FDA took 12 peptides off Category 2 after the people who nominated them withdrew. About BPC-157, FDA’s page still says the agency “lacks sufficient information to know whether the drug would cause harm when administered to humans.” (FDA) Coming off Category 2 “does not render these bulk drug substances eligible for compounding.” (Frier Levitt)
• July 2026: FDA staff proposed that none of the seven peptides be added. The panel recommended six anyway. (NCPA)
• Now: The vote is advisory. As one law firm put it, “Nothing has legally changed yet.” (Mintz) FDA would have to publish a proposed rule, take public comments and then issue a final rule. (Frier Levitt)

How long? Estimates run from 12 to 24 months or longer. (Sheppard Mullin) The last comparable rule took from December 2016 to February 2019. (Buchanan Ingersoll & Rooney) A second panel meeting on five more peptides is expected around February 2027.

Lane 3: “Research use only”

The phrase has a history. FDA requires it on lab diagnostic tests that are still in development: “For Research Use Only. Not for use in diagnostic procedures.” (eCFR)

For any product, FDA looks at what it’s really being sold for. That intent can be shown by “labeling claims, advertising matter, or oral or written statements.” (eCFR)

• February 2025: FDA told a peptide seller that its “research use only” and “not for human consumption” labels didn’t matter. Its website showed the products were drugs meant for people. (FDA warning letter)
• August 24, 2026: FDA sent similar warning letters to several online peptide sellers, calling their products unapproved new drugs. (FDA warning letter)

What it means for you: a research-use-only product is sold for lab work. A legitimate research supplier doesn’t hand out dosing advice or human-use claims. That line is what keeps legitimate research supply legal, and it’s why careful suppliers hold it.

If you compete in tested sports, one more fact. BPC-157 is banned at all times under the World Anti-Doping Agency’s “non-approved substances” class. TB-500 is banned too. (USADA)

Quality is a separate question from legal status. For what testing can and can’t show, read what’s in the other 1%.

Three questions for any peptide headline

Back at the table

Paul gives the rookie the short version. The panel voted. FDA hasn’t acted. And “approved” is the wrong word.

The rookie shrugs. “So, not yet.”

“Not yet,” Paul says. “And maybe not in the form you’re picturing.”

Before you trust a peptide headline, find out which lane it’s in.

Your next step: the next time a headline says “approved,” run the three questions above before you believe it or pass it on.

---

Status as of September 24, 2026. We’ll update this article when FDA publishes a proposed or final rule. This is general information, not legal or medical advice. Paul is a composite, drawn from the kinds of questions readers ask after peptide headlines. The details are illustrative. Research compounds are sold for laboratory research only.

Read next: After the MRI: How to Read a Rotator Cuff Report Without Getting Sold a Surgery